Unsymmetrical DNA cross-linking agents: Combination of the CBI and PBD pharmacophores

Journal of Medicinal Chemistry

Volumn 46, Issue 11, 2003, Pages 2132-2151

  Tercel, Moana ^a   Stribbling, Stephen M ^a   Sheppard, Hilary ^a   Siim, Bronwyn G ^a   Wu, Kent ^a   Pullen, Susan M ^a   Botting, K Jane ^a   Wilson, William R ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

8 [2 [1 (CHLOROMETHYL) 5 HYDROXY 1,2 DIHYDRO 3H BENZ[E]INDOL 3 YL] 2 OXOETHOXY] 7 METHOXY 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPIN 5 ONE; 8 [3 [1 (CHLOROMETHYL) 5 HYDROXY 1,2 DIHYDRO 3H BENZ[E]INDOL 3 YL] 3 OXOPROPOXY] 7 METHOXY 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPIN 5 ONE; 8 [4 [1 (CHLOROMETHYL) 5 HYDROXY 1,2 DIHYDRO 3H BENZ[E]INDOL 3 YL] 4 OXOBUTOXY] 7 METHOXY 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPIN 5 ONE; 8 [[5 [1 (CHLOROMETHYL) 5 HYDROXY 1,2 DIHYDRO 3H BENZ[E]INDOL 3 YL] 5 OXOPENTYL]OXY] 7 METHOXY 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPIN 5 ONE; 8 [[6 (5 HYDROXY 1 METHYL 1,2 DIHYDRO 3H BENZ[E]INDOL 3 YL) 6 OXOHEXYL]OXY] 7 METHOXY 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPIN 5 ONE; 8 [[6 [1 (CHLOROMETHYL) 5 HYDROXY 1,2 DIHYDRO 3H BENZ[E]INDOL 3 YL] 6 OXOHEXYL]OXY] 7 METHOXY 1,2,3,11A TETRAHYDRO 5H PYRROLO[2,1 C][1,4]BENZODIAZEPIN 5 ONE; 8 [[6 [1 (CHLOROMETHYL) 5 HYDROXY 1,2 DIHYDRO 3H BENZ[E]INDOL 3 YL] 6 OXOHEXYL]OXY] 7 METHOXY 2,3 DIHYDRO 1H PYRROLO[2,1 C][1,4]BENZODIAZEPINE 5,11(10H,11AH) DIONE; ADENINE; ANTINEOPLASTIC AGENT; DIMER; DNA; GUANINE; NAKED DNA; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE; SECO 1,2,9,9A TETRAHYDROCYCLOPROPA[C]BENZ[E]INDOL 4 ONE; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL LINE; COLON CARCINOMA; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; CROSS LINKING; CYTOTOXICITY; DNA CROSS LINKING; DRUG ACTIVITY; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; IN VIVO STUDY; NONHUMAN; SEQUENCE ANALYSIS; STATISTICAL SIGNIFICANCE; STRUCTURE ANALYSIS; SURVIVAL TIME; THERMAL ANALYSIS; XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS, ALKYLATING; BENZODIAZEPINES; BENZODIAZEPINONES; COMET ASSAY; CROSS-LINKING REAGENTS; CYCLOPROPANES; DNA, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; INDOLES; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PYRROLES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR CELLS, CULTURED;

EID: 0037911296     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm020526p     Document Type: Article

References (83)

1. Rajski, S. R.; Williams, R. M. DNA Cross-Linking Agents as Antitumor Drugs. Chem. Rev. 1998, 98, 8, 2723-2795.
2. Woynarowski, J. M.; Napier, C.; Trevino, A. V.; Arnett, B. Region-Specific DNA Damage by AT-Specific DNA-Reactive Drugs is Predicted by Drug Binding Specificity. Biochemistry 2000, 39, 9917-9927.
3. Woynarowski, J. M.; Trevino, A. V.; Rodriguez, K. A.; Hardies, S. C.; Benham, C. J. AT-rich Islands in Genomic DNA as a Novel Target for AT-Specific DNA-Reactive Antitumor Drugs. J. Biol. Chem. 2001, 276, 40555-40566.
4. Bando, T.; Iida, H.; Saito, I.; Sugiyama, H. Sequence-Specific DNA Interstrand Cross-Linking by Imidazole-Pyrrole CPI Conjugate. J. Am. Chem. Soc. 2001, 123, 5158-5159.
5. Thurston, D. E. Nucleic Acid Targeting: Therapeutic Strategies for the 21st Century. Br. J. Cancer 1999, 80, 65-85.
6. Boger, D. L.; Johnson, D. S. CC-1065 and the Duocarmycins: Understanding Their Biological Function Through Mechanistic Studies. Angew. Chem., Int. Ed. Engl. 1996, 35, 1438-1474.
7. Thurston, D. E.; Bose, D. S. Synthesis of DNA-Interactive Pyrrolo[2,1-c] [1,4]benzodiazepines. Chem. Rev. 1994, 94, 433-465.
8. Fukuda, Y.; Seto, S.; Furuta, H.; Ebisu, H.; Oomori, Y.; Terashima, S. Cyclopropapyrroloindole (CPI) Bisalkylators. Drugs Future 1998, 23, 1317-1330.
9. Seco-CPI is the ring-opened form of the CPI (1,2,8,8a-tetrahydro-7-methylcyclopropa[c]pyrrolo[3,2-e]indo]-4-one) alkylation sub-unit. In general the seco forms of cyclopropaindolones readily ring close under culture conditions and have the same biological properties as the cyclo parents.
10. Mitchell, M. A.; Kelly, R. C.; Wicnienski, N. A.; Hatzenbuhler, N. T.; Williams, M. G.; Petzold, G. L.; Slightom, J. L.; Siemieniak, D. R. Synthesis and DNA Cross-Linking by a Rigid CPI Dimer, J. Am. Chem. Soc. 1991, 113, 8994-8995.
11. Cross-linking occurs between the adenine marked with an asterisk and that opposite the underlined thymine.
12. Sun, D.; Hurley, L. H. Analysis of the Monoalylation and Cross-Linking Sequence Specificity of Bizelesin, a Bifunctional Alkylation Agent Related to (+)-CC-1065. J. Am. Chem. Soc. 1993, 115, 5925-5933.
13. Carter, C. A.; Waud, W. R.; Li, L. H.; DeKoning, T. F.; McGovren, J. P.; Plowman, J. Preclinical Antitumor Activity of Bizelesin in Mice. Clin. Cancer Res. 1996, 2, 1143-1149.
14. Pitot, H. C.; Reid, J. M.; Sloan, J. A.; Ames, M. M.; Adjei, A. A.; Rubin, J.; Bagniewski, P. G.; Atherton, P.; Rayson, D.; Goldberg, R. M.; Erlichman, C. A Phase I Study of Bizelesin (NSC 615291) in Patients with Advanced Solid Tumors. Clin. Cancer Res. 2002, 8, 712-717.
15. Volpe, D. A.; Tomaszewski, J. E.; Parchment, R. E.; Garg, A.; Flora, K. P.; Murphy, M. J.; Grieshaber, C. K. Myelotoxic Effects of the Bifunctional Alkylating Agent Bizelesin on Human, Canine and Murine Myeloid Progenitor Cells. Cancer Chemother. Pharmacol. 1996, 39, 143-149.
16. (a) Markovic, S. N.; Suman, V. J.; Vukov, A. M.; Fitch, T. R.; Hillman, D. W.; Adjei, A. A.; Alberts, S. R.; Kaur, J. S.; Braich, T. A.; Leitch, J. M.; Creagan, E. T. Phase II Trial of KW2189 in Patients With Advanced Malignant Melanoma. Am. J. Clin. Oncol. 2002, 25, 308-312.
17. (b) Pavlidis, N.; Aamdal, S.; Awada, A.; Calvert, H.; Fumoleau, P.; Sorio, R.; Punt, C.; Verweij, J.; van Oosterom, A.; Morant, R.; Wanders, J.; Hanauske, A-R. Carzelesin Pase II Study in Advanced Breast, Ovarian, Colorectal, Gastric, Head and Neck Cancer, Non-Hodgkin's Lymphoma and Malignant Melanoma: a Study of the EORTC Early Clinical Studies Group (ECSG). Cancer Chemother. Pharmacol. 2000, 46, 167-171.
18. (c) Cristofanilli, M.; Bryan, W. J.; Miller, L. L.; Chang, A. Y-C.; Gradishar, W. J.; Kufe, D. W.; Hortobagyi, G. N. Phase II Study of Adozelesin in Untreated Metastatic Breast Cancer. Anti-Cancer Drugs 1998, 9, 779-782.
19. Mitchell, M. A.; Johnson, P. D.; Williams, M. G.; Aristoff, P. A. Interstrand DNA Cross-Linking with Dimers of the Spirocyclopropyl Alkylating Moiety of CC-1065. J. Am. Chem. Soc. 1989, 111, 6428-6429.
20. (a) Park, H-J.; Kelly, R. C.; Hurley, L. H. The Chemical Evolution of DNA-DNA Interstrand Cross-Linkers That Recognize Mixed AT and GC Sequences. J. Am. Chem. Soc. 1996, 118, 10041-10051.
21. (b) Fukuda, Y.; Seto, S.; Furuta, H.; Ebisu, H.; Oomori, Y.; Terashima, S. Novel Seco Cyclopropa[c]pyrrolo[3,2-e]indole Bisalkylators Bearing a 3,3′-Arylenebisacryloyl Group as a Linker. J. Med. Chem. 2001, 44, 1396-1406.
22. (c) Boger, D. L.; Searcey, M.; Tse, W. C.; Jin, Q. Bifunctional Alkylating Agents Derived from Duocarmycin SA: Potent Antitumor Activity with Altered Sequence Selectivity. Bioorg. Med. Chem. Lett. 2000, 10, 495-498.
23. Jia, G.; Lown, J. W. Design, Synthesis and Cytotoxicity Evaluation of 1-Chloromethyl-5-hydroxy-1,2-dihydro-3H-benz[e]indole (seco-CBI) Dimers. Bioorg. Med. Chem. 2000, 8, 1607-1617.
24. 2: Enhanced Functional Analogues of CC-1065 Incorporating the 1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI) Left-Hand Subunit. J. Org. Chem. 1990, 55, 5823-5832.
25. Bose, D. S.; Thompson, A. S.; Ching, J.; Hartley, J. A.; Berardini, M. D.; Jenkins, T. C.; Neidle, S.; Hurley, L. H.; Thurston, D. E. Rational Design of a Highly Efficient Irreversible DNA Interstrand Cross-Linking Agent Based on the Pyrrolobenzodiazepine Ring System. J. Am. Chem. Soc. 1992, 114, 4939-4941.
26. Bose, D. S.; Thompson, A. S.; Smellie, M.; Berardini, M. D.; Hartley, J. A.; Jenkins, T. C.; Neidle, S.; Thurston, D. E. Effect of Linker Length on DNA-Binding Affinity, Cross-Linking Efficiency and Cytotoxicity of C8-Linked Pyrrolobenzodiazepine Dimers. J. Chem. Soc., Chem. Commun. 1992, 1518-1520.
27. Jenkins, T. C.; Hurley, L. H.; Neidle, S.; Thurston, D. E. Structure of a Covalent Minor Groove Adduct with a Pyrrolobenzodiazepine Dimer: Evidence for Sequence-Specific Interstrand Cross-Linking. J. Med. Chem. 1994, 37, 4529-4537.
28. Walton, M. I.; Goddard, P.; Kelland, L. R.; Thurston, D. E.; Harrap, K. R. Preclinical Pharmacology and Antitumor Activity of the Novel Sequence-Selective DNA Minor-Groove Cross-Linking Agent DSB-120. Cancer Chemother. Pharmacol. 1996, 38, 431-438.
29. Gregson, S. J.; Howard, P. W.; Hartley, J. A.; Brooks, N. A.; Adams, L. J.; Jenkins, T. C.; Kelland, L. R.; Thurston, D. E. Design, Synthesis, and Evaluation of a Novel Pyrrolobenzodiazepine DNA-Interactive Agent with Highly Efficient Cross-Linking Ability and Potent Cytotoxicity. J. Med. Chem. 2001, 44, 737-748.
30. Hartley, J. A.; Spanswick, V. J.; Pedley, B.; Hollingshead, M. G.; Alley, M. C.; Schultz, R.; Gregson, S. J.; Howard, P. H.; Thurston, D. E. In Vitro Antitumor Activity and In Vivo DNA Interstrand Cross-linking by the Novel Pyrrolobenzodiazepine Dimer SJG-136 (NSC 694501). Proceedings of the American Association for Cancer Research; 93rd Annual Meeting, San Francisco, April 6-10, 2002, Vol. 43, Abstract 2432 (http://www.aacr.org).
31. Zhou, Q.; Duan, W.; Simmons, D.; Shayo, Y.; Raymond, M. A.; Dorr, R. T.; Hurley, L. H. Design and Synthesis of a Novel DNA-DNA Interstrand Adenine-Guanine Cross-Linking Agent. J. Am. Chem. Soc. 2001, 123, 4865-4866.
32. Hurley, L. H.; Warpehoski, M. A.; Lee, C-S.; McGovren, J. P.; Scahill, T. A.; Kelly, R. C.; Mitchell, M. A.; Wicnienski, N. A.; Gebhard, I.; Johnson, P. D.; Bradford, V. S. Sequence Specificity of DNA Alkylation by the Unnatural Enantiomer of CC-1065 and Its Synthetic Ananlogues. J. Am. Chem. Soc. 1990, 112, 4633-4649.
33. Boger, D. L.; Yun, W. CBI-TMI: Synthesis and Evaluation of a Key Analogue of the Duocarmycins. Validation of a Direct Relationship between Chemical Solvolytic Stability and Cytotoxic Potency and Confirmation of the Structural Features Responsible for the Distinguishing Behavior of Enantiomeric Pairs of Agents. J. Am. Chem. Soc. 1994, 116, 7996-8006.
34. Fukuyama, T.; Liu, G.; Linton, S. D.; Lin, S-C.; Nishino, H. Total Synthesis of (+)-Porothramycin B. Tetrahedron Lett. 1993, 34, 2577-2580.
35. (a) Boger, D. L.; McKie, J. A. An Efficient Synthesis of 1,2,9,9a-Tetrahydrocyclopropa[c]benz[e]indol-4-one (CBI): An Enhanced and Simplified Analogue of the CC-1065 and Duocarmycin Alkylation Subunits. J. Org. Chem. 1995, 60, 1271-1275.
36. (b) Boger, D. L.; Boyce, C. W.; Garbaccio, R. M.; Searcey, M. Synthesis of CC-1065 and Duocarmycin Analogues via Intramolecular Aryl Radical Cyclization of a Tethered Vinyl Chloride. Tetrahedron Lett. 1998, 39, 2227-2230.
37. (c) Gieseg, M. A.; Matejovic J.; Denny, W. A. Comparison of the Patterns of DNA Alkylation by Phenol and Amino seco-CBI-TMI Compounds: Use of a PCR Method for the Facile Preparation of Single End-Labeled Double-Stranded DNA. Anti-Cancer Drug Design 1999, 14, 77-84.
38. Petrusek, R. L.; Anderson, G. L.; Garner, T. F.; Fannin, Q. L.; Kaplan, D. J.; Zimmer, S. G.; Hurley, L. H. Pyrrolo[1,4]- benzodiazepine Antibiotics. Proposed Structures and Characteristics of the In Vitro Deoxyribonucleic Acid Adducts of Anthramycin, Tomaymycin, Sibiromycin, and Neothramycins A and B. Biochemistry 1981, 20, 1111-1119.
39. Althuis, T. H.; Hess, H-J. Synthesis and Identification of the Major Metabolites of Prazosin Formed in Dog and Rat. J. Med. Chem. 1977, 20, 146-149.
40. (a) Sagnou, M. J.; Howard, P. H.; Gregson, S. J.; Eno-Amooquaye, E.; Burke, P. J.; Thurston, D. E. Design and Synthesis of Novel Pyrrolobenzodiazepine (PBD) Prodrugs for ADEPT and GDEPT. Bioorg. Med. Chem. Lett. 2000, 10, 2083-2086.
41. (b) Thurston, D. E.; Howard, P. W. Preparation of Pyrrolobenzodiazepines (PBDs) as Antitumor Antibiotics. PCT Int. Appl. WO 0012507, 2000.
42. Wright, I. G.; Ashbrook, C. W.; Goodson, T.; Kaiser, G. V.; Van Heyningen, E. M. Chemistry of Cephalosporin Antibiotics. 23. 2-Methyl- and 2-methylenecephalosporins. J. Med. Chem. 1971, 14, 420-426.
43. Just, G.; Grozinger, K. A Selective, Mild Cleavage of Trichloroethyl Esters, Carbamates, and Carbonates to Carboxylic Acids, Amines, and Phenols using Zinc/Tetrahydrofuran/pH4.2-7.2 Buffer. Synthesis 1976, 457-459.
44. Jou, G.; Gonzalez, I.; Albericio F.; Lloyd-Williams, P.; Giralt, E. Total Synthesis of Dehydrodidemnin B. Use of Uronium and Phosphonium Salt Coupling Reagents in Peptide Synthesis in Solution. J. Org. Chem. 1997, 62, 354-366.
45. (a) Baraldi, P. G.; Balboni, G.; Cacciari, B.; Guiotto, A.; Manfredini, S.; Romagnoli, R.; Spalluto, G.; Thurston, D. E.; Howard, P. H.; Bianchi, N.; Rutigliano, C.; Mischiati, C.; Gambari, R. Synthesis, In Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrolo[2,1-c] [1,4]-benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers. J. Med. Chem. 1999, 42, 5131-5141.
46. (b) Thurston, D. E.; Bose, D. S.; Howard, P. H.; Jenkins, T. C.; Leoni, A.; Baraldi, P. G.; Guiotto, A.; Cacciari, B.; Kelland, L. R.; Foloppe, M-P.; Rault, S. Effect of A-Ring Modifications on the DNA-Binding Behavior and Cytotoxicity of Pyrrolo [2,1-c] [1,4]benzodiazepines. J. Med. Chem. 1999, 42, 1951-1964.
47. Dalcanale, E.; Montanari, F. Selective Oxidation of Aldehydes to Carboxylic Acids with Sodium Chlorite-Hydrogen Peroxide. J. Org. Chem. 1986, 51, 567-569.
48. Seltzman, H. H.; Berrang, B. D. Nickel Boride Reduction of Aryl Nitro Compounds. Tetrahedron Lett. 1993, 34, 3083-3086.
49. Kunz, H.; Unverzagt, C. Protective Group Dependent Stability of Intersaccharide Bond. Synthesis of Fucosylchitobiose-Glucopeptides. Angew. Chem. 1988, 100, 1763-1765.
50. Thurston, D. E.; Murty, V. S.; Langley, D. R.; Jones, G. B. O-Debenzylation of a Pyrrolo[2,1-c] [1,4]benzodiazepine in the Presence of a Carbinolamine Functionality: Synthesis of DC-81. Synthesis 1990, 81-84.
51. Molina, P.; Diaz, I.; Tarraga, A. Synthesis of Pyrrolo[2,1-c] [1,4]-benzodiazepines via an Intramolecular Aza-Wittig Reaction. Synthesis of the Antibiotic DC-81. Tetrahedron 1995, 51, 5617-5630.
52. Bose, D. S.; Jones, G. B.; Thurston, D. E. New Approaches to Pyrrolo[2,1-c] [1,4]benzodiazepines: Synthesis, DNA-Binding and Cytotoxicity of DC-81. Tetrahedron 1992, 48, 751-758.
53. D]= +135°, but this has been attributed to likely epimerization during the isolation steps.
54. 3 was +567°, but this does not necessarily represent the equilibrium situation. For further discussion see Supporting Information.
55. Thurston, D. E.; Bose, D. S.; Thompson, A. S.; Howard, P. H.; Leoni, A.; Croker, S. J.; Jenkins, T. C.; Neidle, S.; Hartley, J. A.; Hurley, L. H. Synthesis of Sequence-Selective C8-Linked Pyrrolo[2,1-c] [1,4]benzodiazepine DNA Interstrand Cross-Linking Agents. J. Org. Chem. 1996, 61, 8141-8147.
56. Jones, G. B.; Davey, C. L.; Jenkins, T. C.; Kamal, A.; Kneale, G. G.; Neidle, S.; Webster, G. D.; Thurston, D. E. The Non-Covalent Interaction of Pyrrolo[2,1-c] [1,4]benzodiazepine-5,11-diones with DNA. Anti-Cancer Drug Design 1990, 5, 249-264.
57. 13e was found to have almost completely hydrolyzed on storage, so following Aloc deprotection, an extra EDCI-mediated dehydration step was used to reform the N10/C11 amide bond.
58. Boger, D. L.; Mesini, P. Design, Synthesis and Evaluation of CC-1065 and Duocarmycin Analogues Incorporating the 2,3,10,10a- Tetrahydro-1H-cyclopropa[d]benzo[f]quinol-5-one (CBQ) Alkylation Subunit: Identification and Structural Origin of Subtle Stereoelectronic Features That Govern Reactivity and Regioselectivity. J. Am. Chem. Soc. 1994, 116, 11335-11348.
59. Wilson, W. R.; Denny, W. A.; Pullen, S. M.; Thompson, K. M.; Li, A. E.; Patterson, L. H.; Lee, H. H. Tertiary Amine N-Oxides as Bioreductive Drugs: DACA N-Oxide, Nitracrine N-Oxide and AQ4N. Br. J. Cancer 1996, 74 (Suppl. XXVII), S43-S47.
60. Marshall, E. S.; Finlay, G. J.; Matthews, J. H. L.; Shaw, J. H. F.; Nixon, J.; Baguley, B. C. Microculture-Based Chemosensitivity Testing: A Feasibility Study Comparing Freshly Explanted Human Melanoma Cells With Human Melanoma Cell Lines. J. Natl. Cancer Inst. 1992, 84, 340-345.
61. Hoeijmakers, J. H. J.; Bootsma, D. Molecular Genetics of Eukaryotic DNA Excision Repair. Cancer Cells 1990, 2, 311-320.
62. Hoy, C. A.; Salazar, E. P.; Thompson, L. H. Rapid Detection of DNA-Damaging Agents Using Repair-Deficient CHO Cells. Mutat. Res. 1984, 130, 321-332.
63. Boger, D. L.; Garbaccio, R. M. Shape-Dependent Catalysis: Insights into the Source of Catalysis for the CC-1065 and Duocarmycin DNA Alkylation Reaction. Acc. Chem. Res. 1999, 32, 1043-1052.
64. (a) Monks, A.; Scudiero, D. A.; Johnson, G. S.; Paull, K. D.; Sausville, E. A. The NCI Anti-Cancer Drug Screen: A Smart Screen to Identify Effectors of Novel Targets. Anti-Cancer Drug Design 1997, 12, 533-541.
65. (b) Monks, A.; Scudiero, D.; Skehan, P.; Shoemaker, R.; Paull, K.; Vistica, D.; Hose, C.; Langley, J.; Cronise, P.; Vaigro-Wolff, A.; Gray-Goodrich, M.; Campbell, H.; Mayo, J.; Boyd, M. Feasibility of a High-Flux Anticancer Drug Screen Using a Diverse Panel of Cultured Human Tumor Cell Lines. J. Natl. Cancer Inst. 1991, 83, 757-766.
66. Paull, K. D.; Shoemaker, R. H.; Hodes, L.; Monks, A.; Scudiero, D. A.; Rubinstein, L.; Plowman, J.; Boyd, M. R. Display and Analysis of Patterns of Differential Activity of Drugs Against Human Tumor Cell Lines: Development of Mean Graph and COMPARE Algorithm. J. Natl. Cancer Inst. 1989, 81, 1088-1092.
67. Hartley, J. A.; Berardini, M. D.; Souhami, R. L. An Agarose Gel Method for the Determination of DNA Interstrand Cross-linking Applicable to the Measurement of the Rate of Total and "Second-Arm" Cross-link Reactions. Anal. Biochem. 1991, 193, 131-134.
68. Lee, C-S.; Gibson, N. W. DNA Damage and Differential Cytotoxicity Produced in Human Carcinoma Cells by CC-1065 Analogues, U-73,975 and U-77,779. Cancer Res. 1991, 51, 6586-6591.
69. Reynolds, V. L.; Molineux, I. J.; Kaplan, D. J.; Swenson, D. H.; Hurley, L. H. Reaction of the Antitumor Antibiotic CC-1065 with DNA. Location of the Site of Thermally Induced Strand Breakage and Analysis of DNA Sequence Specificity. Biochemistry 1985, 24, 6228-6237.
70. (a) Warpehoski, M. A.; Harper, D. E.; Mitchell, M. A.; Monroe, T. J. Reversibility of the Covalent Reaction of CC-1065 and Analogues with DNA. Biochemistry 1992, 31, 2502-2508.
71. (b) Boger, D. L.; Yun, W. Reversibility of the Duocarmycin A and SA DNA Alkylation Reaction. J. Am. Chem. Soc. 1993, 115, 9872-9873.
72. See Supporting Information for graphs of the individual data points and fitted curves for each of the compounds.
73. 22 Although similar to the value found here the results are not directly comparable since a different DNA sequence (pBR322 plasmid, 4400 bp) and exposure time (2 h) were used.
74. Fairbairn, D. W.; Olive, P. L.; O'Neill, K. L. The Comet Assay: a Comprehensive Review. Mutat. Res. 1995, 339, 37-59.
75. 32P-End-Labeled Double-Stranded DNA for Binding Studies: Development of a Protocol for Examination of Functional Features of (+)-CC-1065 and the Duocarmycins that Contribute to their Sequence-Selective DNA Alkylation Properties. Tetrahedron 1991, 47, 2661-2682.
76. Smellie, M.; Kelland, L. R.; Thurston, D. E.; Souhami, R. L.; Hartley, J. A. Cellular Pharmacology of Novel C8-Linked Anthramycin-Based Sequence-Selective DNA Minor Groove Cross-Linking Agents. Br. J. Cancer 1994, 70, 48-53.
77. Paull, K. D.; Hamel, E.; Malspeis, L. Prediction of Biochemical Mechanism of Action from the In Vitro Antitumor Screen of the National Cancer Institute. In Cancer Chemotherapeutic Agents, Foye, W. O., Ed.; American Chemical Society: Washington, DC, 1995; pp 9-45.
78. 50 comparison.
79. Seuring, B.; Seebach, D. Syntheses and Determinations of the Absolute Configurations of Norpyrenophorin, Pyrenophorin, and Vermiculine. Justus Liebigs Ann. Chem. 1978, 12, 2044-2073.
80. Trost, B. M.; Verhoeven, T. R. Cyclization Catalyzed by Palladium(0). Initial Studies and Macrolide Formation. J. Am. Chem. Soc. 1980, 102, 4743-4763.
81. Alexander, J.; Renyer, M. L.; Veerapanane, H. A Convenient Method for the Conversion of Halides to Alcohols. Synth. Commun. 1995, 25, 3875-3881.
82. Tercel, M.; Lee, A. E.; Hogg, A.; Anderson, R. F.; Lee, H. H.; Siim, B. G.; Denny, W. A.; Wilson, W. R. Hypoxia-Selective Antitumor Agents. 16. Nitroarylmethyl Quaternary Salts as Bioreductive Prodrugs of the Alkylating Agent Mechlorethamine. J. Med. Chem. 2001, 44, 3511-3522.
83. White, R. J.; Phillips, D. R. Transcriptional Analysis of Multisite Drug-DNA Dissociation Kinetics: Delayed Termination of Transcription by Actinomycin D. Biochemistry 1988, 27, 9122-9132.